Guidance in the Red / Amber List serves ONLY to define where clinical and prescribing responsibility for the listed medicines should lie in terms of governance and safety.
- Inclusion in this list does NOT imply the medicine has been accepted for use via Managed Entry, does NOT imply endorsement of use, and does NOT take account of the cost implications of use of a particular medicine.
- Prescribers should use this list in conjunction with guidance on the Managed entry process for medicines, and the NI formulary which includes information on current cost effective choices.
- As far as possible, new specialist medicines are added to the list at the point when they are granted a UK product licence. In some instances this may be prior to the medicine being launched.
The table below lists specialist medicines. Users should search by generic name where possible. Brand names listed are not exhaustive.
Show All Entries A-B C-D E-J K-M N-R S-Z
| Approved Name | Example Trade Names | Context | Status | Guidance | New Entry |
|---|---|---|---|---|---|
| Ketamine | Ketalar, Ketamine oral solution | Palliative Care (outside licence) | Amber | Ketamine Shared Care Guideline | |
| Ketamine | Ketalar, Ketamine oral solution | Neuropathic pain | Red | ||
| Ketanserin | Sufrexal | Red | |||
| Ketoconazole HRA | Ketoconazole HRA | HRA formulation (for Cushing's syndrome) only | Red | ||
| L-Tryptophan | Optimax | Amber | No Shared Care Guideline Required (Click for info) | ||
| Lamivudine | Zeffix | Red | |||
| Lamivudine with dolutegravir | Dovato | Red | |||
| Lamivudine with tenofovir disoproxil | Red | ||||
| Lamivudine with tenofovir disoproxil and doravirine | Delstrigo | Red | |||
| Lanadelumab | Takhzyro | Red | |||
| Lanreotide | Somatuline | Neuroendocrine tumours and acromegaly. Within licence | Amber | Lanreotide Shared Care Guideline | |
| Lanreotide | Somatuline | Outside licence | Red | ||
| Lapatinib | Tyverb | Red | |||
| Larotrectinib | Vitrakvi | Red | |||
| Leflunomide | Arava | Amber | Leflunomide Shared Care Guideline | ||
| Lenacapavir | Sunlenca | Red | |||
| Lenalidomide | Revlimid | Red | |||
| Lenograstim | Granocyte | Red | |||
| Lenvatinib | Lenvima | Red | |||
| Letermovir | Prevymis | Red | |||
| Leuprorelin | Prostap, Lutrate | When used for treatment of infertility | Red | ||
| Levofloxacin nebuliser solution | Quinsair | Red | |||
| Linezolid | Zyvox | Red | |||
| Liothyronine | Management of thyroid disorders | Amber | Liothyronine Shared Care Guideline | ||
| Lipegfilgrastim | Lonquex | Red | |||
| Lisdexamfetamine | Elvanse | Amber | Lisdexamfetamine Shared Care Guideline | ||
| Lithium | Camcolit, Liskonum, Priadel | Amber | Lithium Shared Care Guideline | ||
| Lofexidine | BritLofex | Red | |||
| Lomitapide | Lojuxta | Red | |||
| Lomustine | Red | ||||
| Loncastuximab tesirine | Zynlonta | Red | |||
| Lopinavir + ritonavir | Kaletra | Red | |||
| Lorlatinib | Lorviqua | Red | |||
| Lumacaftor (with ivacaftor) | Orkambi | Red | |||
| Lumasiran | Oxlumo | Red | |||
| Luspatercept | Reblozyl | Red | |||
| Lusutrombopag | Mulpleo | Red | |||
| Lutetium (177Lu) vipivotide tetraxetan | Pluvicto | Red | |||
| Lutetium(177Lu) oxodotreotide | Lutathera | Red | |||
| Lutropin | Luveris, Pergoveris | Red | |||
| Macitentan | Opsumit | Red | |||
| Maraviroc | Celsentri | Red | |||
| Maribavir | Livtencity | Red | |||
| Mecasermin | Increlex | Red | |||
| Melatonin | Amber | Melatonin Shared Care Guideline | |||
| Melphalan | Alkeran | Red | |||
| Mepolizumab | Nucala | Red | |||
| Mercaptamine (oral) | Cystagon, Procysbi | Amber | No Shared Care Guideline Required (Click for info) | ||
| Mercaptamine eyedrops | Cystadrops | Amber | No Shared Care Guideline Required (Click for info) | ||
| Mercaptopurine | For non-cancer indications | Amber | Mercaptopurine Shared Care Guideline | ||
| Mercaptopurine | When used as a systemic anti-cancer therapy | Red | |||
| Methotrexate | Subcutaneous (Metoject) | For non-cancer indications | Amber | Methotrexate subcutaneous Shared Care Guideline | |
| Methotrexate | oral | For non-cancer indications | Amber | Methotrexate oral Shared Care Guideline | |
| Methotrexate | oral | When used as a systemic anti-cancer therapy | Red | ||
| Methotrexate | parenteral (other than subcutaneous) | All indications | Red | ||
| Methyl aminolevulinate cream | Metvix | Red | |||
| Methylphenidate | Ritalin, Equasym, Concerta XL, Delmosart | For attention deficit hyperactivity disorder in adults and children 6 years and over, within NICE recommended doses. | Amber | Methylphenidate Shared Care Guideline | |
| Methylphenidate | Ritalin, Equasym, Concerta XL, Delmosart | For attention deficit hyperactivity disorder in children under 6 years, or doses over NICE recommended doses. | Red | ||
| Metreleptin | Myalepta | Red | |||
| Mexiletine | Non-proprietary | Cardiology | Amber | Shared Care Guideline In Development | |
| Midostaurin | Red | ||||
| Migalastat | Galfold | Red | |||
| Miglustat | Zavesca | Red | |||
| Mitotane | Lysodren | Red | |||
| Mobocertinib | Exkivity | Red | |||
| Moclobemide | Manerix | Amber | No Shared Care Guideline Required (Click for info) | ||
| Modafinil | Provigil | Amber | No Shared Care Guideline Required (Click for info) | ||
| Mogamulizumab | Poteligeo | Red | |||
| Monacog alfa | BeneFix | Red | |||
| Moroctocgog alfa | ReFacto | Red | |||
| Mosunetuzumab | Lunsumio | Red | |||
| Mycophenolate mofetil | CellCept | Non transplant indications | Amber | Mycophenolate mofetil (other non-transplant indications) shared care guideline | |
| Mycophenolate mofetil | CellCept | Immunosuppressant post transplantation | Amber | Mycophenolate mofetil Post Transplant Shared Care Guideline |